What is the most recent earnings date for BBIO stock?
BRIDGEBIO PHARMA INC (BBIO) last reported earnings on 2/24/2026.
BRIDGEBIO PHARMA INC (BBIO) Earnings History & Surprises
NASDAQ:BBIO • US10806X1028
Current stock price
72.28 USD
-0.87 (-1.19%)
At close:
73 USD
+0.72 (+1%)
After Hours:
BBIO Earnings overview
Past quarterly earnings results for BRIDGEBIO PHARMA INC (BBIO), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- Apr 30, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.70
- Revenue Estimate
- 182.29M
Last Reported
Most Recent- Release Date
- Feb 24, 2026
- Period
- Q4 / 2025
- EPS Reported
- -$1.00
- EPS Surprise
- -32.11%
- Revenue Surprise
- 2.94%
Beat Rate
Last 8 Quarters 56%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -1.00 | -0.76 | -32.11% | 28.57% | 154.178M | 149.78M | 2.94% | 2,521.18% |
| Q3 2025 | -0.95 | -0.91 | -4.81% | 13.64% | 120.7M | 108.51M | 11.23% | 4,318.01% |
| Q2 2025 | -0.95 | -0.86 | -10.44% | -143.59% | 110.565M | 93.238M | 18.58% | 4,999.86% |
| Q1 2025 | -0.88 | -0.94 | 6.56% | -340.00% | 116.633M | 63.179M | 84.61% | -44.76% |
| Q4 2024 | -1.40 | -1.15 | -21.38% | -45.83% | 5.882M | 3.549M | 65.74% | 237.08% |
| Q3 2024 | -1.10 | -1.00 | -10.20% | -1.85% | 2.732M | 3.837M | -28.80% | -33.22% |
| Q2 2024 | -0.39 | -1.09 | 64.07% | 60.20% | 2.168M | 3.641M | -40.46% | 32.11% |
| Q1 2024 | -0.20 | -0.78 | 74.34% | 78.26% | 211.12M | 14.314M | 1,374.92% | 11,461.88% |
| Q4 2023 | -0.96 | -0.93 | -3.37% | -4.35% | 1.745M | 6.353M | -72.53% | -6.68% |
| Q3 2023 | -1.08 | -0.83 | -29.83% | -16.13% | 4.091M | 4.118M | -0.66% | 1,103.24% |
| Q2 2023 | -0.98 | -0.85 | -15.29% | -1,300.00% | 1.641M | 3.053M | -46.25% | -97.77% |
| Q1 2023 | -0.92 | -0.85 | -8.52% | 22.69% | 1.826M | 3.443M | -46.96% | 8.05% |
| Q4 2022 | -0.92 | -0.87 | -5.84% | 8.91% | 1.87M | 4.615M | -59.48% | -85.49% |
| Q3 2022 | -0.93 | -1.01 | 8.30% | 12.26% | 340K | 8.063M | -95.78% | -85.47% |
| Q2 2022 | -0.07 | -0.64 | 89.13% | 89.39% | 73.75M | 16.389M | 350.00% | 36.52% |
| Q1 2022 | -1.19 | -1.13 | -5.11% | -0.85% | 1.69M | 4.789M | -64.71% | 267.39% |
| Q4 2021 | -1.01 | -0.89 | -14.11% | - | 12.89M | 22.009M | -41.43% | 10,641.67% |
| Q3 2021 | -1.06 | -0.92 | -15.33% | -8.16% | 2.34M | 17.706M | -86.78% | -71.22% |
| Q2 2021 | -0.66 | -0.96 | 31.27% | 35.92% | 54.02M | 35.536M | 52.01% | - |
| Q1 2021 | -1.18 | -0.75 | -56.60% | -51.28% | 460K | 31.091M | -98.52% | - |
| Q4 2020 | -1.01 | -0.87 | -16.65% | - | 120K | 17.269M | -99.31% | - |
| Q3 2020 | -0.98 | -0.94 | -4.43% | - | 8.13M | 8.772M | -7.32% | - |
| Q2 2020 | -1.03 | -0.79 | -30.80% | - | - | - | ||
| Q1 2020 | -0.78 | -0.68 | -13.89% | - | - | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
1
Average EPS beat (4)
-10.20%
Max EPS beat (4)
6.56%
Min EPS beat (4)
-32.11%
Revenue beat statistics
Revenue beat (4)
4
Average Revenue beat (4)
29.34%
Max Revenue beat (4)
84.61%
Min Revenue beat (4)
2.94%
Analysis
In the last 4 quarters, BBIO has beaten EPS estimates in 1 out of 4 releases
BBIO has consistently beaten revenue estimates in all past 4 earnings releases
In the last 4 quarters, BBIO reported -10.2% below the EPS estimates on average.
In the last 4 quarters, BBIO has beaten the revenue estimates by 29.3% on average.
Related analysis
BRIDGEBIO PHARMA INC / BBIO Earnings FAQ
Did BBIO stock beat earnings estimates in the most recent quarter?
BRIDGEBIO PHARMA INC (BBIO) missed EPS estimates and beat revenue estimates in the most recent quarter.
What percentage of the time does BBIO stock beat earnings estimates?
In the last 4 quarters, BRIDGEBIO PHARMA INC (BBIO) has beaten EPS estimates in 1 out of 4 releases.